BenchSci’s vision is to exponentially increase the speed and quality of life-saving research by empowering scientists with the world’s most advanced biomedical artificial intelligence.

Backed by F-Prime, Gradient Ventures (Google’s AI fund), Inovia Capital, and TCV, our platform accelerates science at 16 of the top-20 pharmaceutical companies, and over 4,300 leading research centers worldwide.

We’re a remote-first company recognized for our impact and culture as a Deloitte Tech Fast 50TM, CIX Top 10 Growth, Great Place to Work®, and top-ranked organization on Glassdoor.

500 Startups Canada

Afore Capital

Radical Ventures

Gradient Ventures

Golden Ventures

Inovia Capital

F-Prime Capital

Northleaf Capital Partners

Real Ventures

Generation Investment Management

BenchSci

The greatest opportunity for AI and GenAI in drug discovery lies in unraveling the complexities of disease biology. 

At BenchSci, we are excited to accelerate our efforts as we work towards our mission to improve the speed and quality of R&D, helping deliver life-changing medicines to patients faster. Check out our latest blog post from BenchSci CEO & Co-Founder Liran Belenzon (he/him), where he explores: 

✔ The pivotal role of GenAI in pharma R&D
✔ How BenchSci’s ASCEND is shaping the future of drug discovery—the disease biology GenAI platform for pharma R&D
✔ The promising future of GenAI in revolutionizing drug discovery 

https://lnkd.in/gNBihdDV

#GenAI #artificialintelligencetechnology 

Earlier today, we shared with our team the difficult news that we are implementing company-wide workforce changes. This decision was not made lightly and resulted in BenchSci saying goodbye to a group of incredibly talented individuals. The decision is a result of shifts in the economic environment, operational efficiencies, and adaptation to technological advancements, specifically Generative AI.

We believe that Generative AI will continue to reshape preclinical R&D and have a substantial positive impact on our customers. As we look towards our future, these changes will allow us to further our investment in Generative AI and work toward making drug discovery more efficient and help bring new medicine to patients faster. 

We are extremely thankful to every BenchScier for their continued dedication and partnership and are fully committed to supporting them through this transition.  

Earlier today, Google Cloud unveiled its new MedLM technology, its latest medically tuned model. 

As an early adopter of LLMs and leader in Biomed AI R&D, BenchSci was among a select group of exclusive partners with early access to MedLM. Hear more about how we're integrating MedLM into our proprietary ASCEND technology to accelerate a best-in-class Biomarker solution from BenchSci Co-Founder and CEO, Liran Belenzon (he/him), who spoke with CNBC.

https://lnkd.in/dYm8My9N

“As a company that values continuous improvement of ourselves and our world, we consider the work and commitment to DEI to be our collective responsibility. Not only is it the right thing to do for our business, it's the right thing to do—period.” Liran Belenzon (he/him)

Today, Great Place to Work® Canada unveiled its 2023 Best Places to Work for Inclusion list, which highlights our ongoing dedication to building and fostering an inclusive environment at BenchSci. 

This recognition comes as a result of every single BenchScier. The work we’ve done and continue to do to create a fair and welcoming environment, is a testament to the dedication of BenchSciers across the entire company. 

Check out our latest blog post from BenchSci’s Diversity, Equity, and Inclusion Program Manager, Shelby Reaburn who spoke with (some of the many) BenchSciers who continue to shape and refine our culture every day including, Christopher Guest, Miya Badley, Wisam Zaghal, Jordan Newington, PhD, Wai Chung Hon, P.Eng., CSM, and Fernando José Suarez Saiz.

https://lnkd.in/gX_QaJpu

#Gptwcertified #Inclusive4All #Bestworkplaces #inclusion #diversity

A few weeks ago, BenchSciers, including members of our Black@BenchSci ERG, attended the largest tech conference for Black professionals, the BFUTR conference in Toronto. This year, we expanded our partnership to have a booth, which allowed us to engage with over 400 individuals, forging valuable connections and expanding our talent pipeline. 

Check out our latest blog post to hear more from Black@BenchSci's Community Manager, Amalia Ward, and BenchSci's Co-Founder and Chief Data Officer, Elvis Wianda.

#BFUTR2023 #BPTN #OBSIDI

https://lnkd.in/gskcQGFg

Tetra Bio-Pharma is a biopharmaceutical company focused on cannabinoid-based drug discovery and development.

Tetra Bio-Pharma

Cyclica is a biotechnology company specializing in AI-augmented drug discovery and polypharmacology.

Cyclica

Semex is a biotechnology company focused on leveraging machine learning and AI for drug discovery and development.

Semex

Atomwise is a leader in using AI for small molecule drug discovery.

Atomwise

Deep Genomics is a biotechnology company specializing in AI-driven genetic medicine.

Deep Genomics

Valence is a biotechnology company focused on AI-driven drug discovery and development.

Valence

Flywheel is a company specializing in data management and workflow solutions for scientific research.

Flywheel

Sapio Sciences provides laboratory information management systems (LIMS) and data management solutions for scientific research.

Sapio Sciences

Benchling offers a platform for life science R&D, including molecular biology, bioinformatics, and collaboration tools.

Benchling

Xellar is a biotech company utilizing Wet-AI and machine learning for drug discovery and development.

Xellar, Inc.

BenchSci is an AI-powered platform that aids scientists in experiment decision-making and accelerates drug discovery by providing an unmatched understanding of disease biology.

news impact assignment basic	general	Mar 4, 2024 10:24 PM	663bc609
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 4, 2024 10:24 PM	851b3783
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Mar 4, 2024 10:24 PM	062bbedd
translate crunchbase fundingrounds	general
peers	general
news basic	general	Mar 4, 2024 10:24 PM	8964faee
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:BENCHSCI

BenchSci